Cyto-Mine® Chroma: Sphere Fluidics’ Advanced Multiplexing Platform

Sphere Fluidics has unveiled Cyto-Mine® Chroma, the next generation of their flagship Cyto-Mine platform. This cutting-edge technology expands on their pioneering droplet-based microfluidics solution for single-cell analysis and isolation. Designed for researchers seeking to improve precision and throughput, Cyto-Mine Chroma introduces a four-color laser system that enables multiplexing, significantly expanding its application range in functional single-cell screening.

Cyto-Mine Chroma is a versatile tool for high-throughput functional analysis, capable of processing millions of cells per hour. By leveraging advanced picodroplet technology, it encapsulates individual cells for functional assessment and selection. This second-generation platform is designed to streamline complex workflows by enabling single-step screening of cell viability, productivity, and target specificity, all within a single droplet.

With an anticipated launch in Q1 2025, the Cyto-Mine Chroma platform is set to revolutionize areas like antibody discovery and cell therapy. Its ability to reduce project timelines and lower costs makes it an invaluable addition to any research laboratory.

Key Features:

• Four-color laser and detector system for enhanced multiplexing
• Best-in-class throughput for functional screening of millions of cells per hour
• Single-step analysis of cell viability, productivity, and target specificity
• Applications in antibody discovery, cell therapy, and cell line development
• Future-proof design with expandable capabilities through upgrade modules